Long-term data show durable survival benefits with Opdivo (nivolumab) plus Yervoy, (ipilimumab), including five-year results in renal cell carcinoma and three-year results in malignant pleural mesothelioma

Phase 3 data from RELATIVITY-047 demonstrate prolonged benefit beyond initial treatment of the LAG-3 blocking antibody relatlimab and PD-1 inhibitor nivolumab fixed-dose combination for patients with previously untreated unresectable or metastatic melanoma

Updated pivotal Phase 3 data from CheckMate -577 reinforce the benefit of Opdivo in earlier stages of esophageal and gastroesophageal cancers

Bristol Myers Squibb (NYSE: BMY) today announced that data reinforcing the potential of immunotherapies to impact clinical outcomes for patients will be featured at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress from September 16-21. Research demonstrating the durable, long-term benefits of Opdivo plus Yervoy in advanced or metastatic cancers, growing evidence supporting the use of Opdivo in earlier-stage cancers, and results for combinations with novel agents such as the investigational LAG-3 blocking antibody relatlimab will be presented among approximately 36 Bristol Myers Squibb-sponsored studies, investigator-sponsored studies and collaborations at the Congress.

Since immune checkpoint inhibitors were introduced more than a decade ago, they have played a transformational role in treating cancers with high unmet need, and most importantly, helping people with cancer live longer, said Samit Hirawat, M.D. , executive vice president, chief medical officer, Global Drug Development, Bristol Myers Squibb. Our data at this years ESMO show that Opdivo and Opdivo -based regimens, including combinations with our immune checkpoint inhibitor Yervoy and our third distinct immune checkpoint inhibitor relatlimab, have the potential to help advance the standard of care in both metastatic and earlier stages of cancer.

Key data being presented by Bristol Myers Squibb at ESMO 2021 include:

Summary of Presentations

*All times noted are Central European Summer Time (CEST)

Abstract Title




Session Title




Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate- 577

Dr. Markus Moehler




Thursday, September 16,

8:30 CEST


Nivolumab (NIVO) Plus Chemotherapy (Chemo) or Ipilimumab (IPI) vs Chemo as First-Line (1L) Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Study

Dr. Yelena Janjigian


Presidential Symposium 2

Sunday, September 19,

16:12-16:27 CEST

Channel 1


Conditional survival and 5-year follow-up in CheckMate 214: first-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

Dr. Robert Motzer




Thursday, September 16,

8:30 CEST


First-line nivolumab + cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial

Dr. Camillo Porta




Thursday, September 16,

8:30 CEST


CheckMate 9KD cohort A2 final analysis: nivolumab (NIVO) + rucaparib for chemotherapy (CT)-nave metastatic castration-resistant prostate cancer (mCRPC)

Dr. Daniel Petrylak



Mini Oral Session Genitourinary Tumours, Prostate

Sunday, September 19,

17:55-18:00 CEST

Channel 2

Head and Neck

Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651

Dr. Athanassios Argiris

Proffered Paper


Proffered Paper Session Head and Neck Cancer, Excl. Thyroid

Monday, September 20,

13:40-13:50 CEST

Channel 1


First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients with unresectable malignant pleural mesothelioma: 3-year update from CheckMate- 743

Dr. Solange Peters

Proferred Paper


Proffered Paper Session Non-Metastatic NSCLC and Other Thoracic Malignancies

Friday, September 17,

13:4013:50 CEST

Channel 2

RELATIVITY-104: first-line relatlimab (RELA) + nivolumab (NIVO) with chemotherapy vs. NIVO with chemotherapy in stage IV or recurrent non-small cell lung cancer (NSCLC) a phase 2, randomized, double-blind study

Dr. Daniel Morgensztern




Thursday, September 16,

8:30 CEST



Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: additional efficacy in RELATIVITY-047

Dr. Stephen Hodi



Proffered Paper Session Melanoma and Other Skin Tumours

Saturday, September 18,

13:30-14:50 CEST Channel 4

CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM)

Dr. Hussein Tawbi



Mini Oral Session Melanoma and Other Skin Tumours

Monday, September 20,

17:35-17:40 CEST Channel 2

Early Development

A phase 2 randomized study of BMS-986012, an antifucosyl-GM1 monoclonal antibody, plus carboplatin, etoposide, and nivolumab (NIVO) as first-line (1L) therapy in patients with extensive-stage small cell lung cancer (ES-SCLC)

Dr. Quincy Chu

Continue reading here:

Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *